AI-assisted, human-published
08/13/2024 /Technology
Pelage Pharmaceuticals Initiates Phase 2a Trial for PP405, Raises $14 Million in Series A-1 Funding
Pelage Pharmaceuticals has commenced the Phase 2a clinical trial for PP405, a new topical small molecule aimed at treating androgenetic alopecia. Additionally, the company secured $14 million in Series A-1 funding led by GV.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com